$ATHE News

Alterity Therapeutics Presents On Multiple System Atrophy Program Including Its Novel Imaging And Biomarker Approach, Phase 2 Data, And Current Plans To Advance ATH434 Into Phase 3 Clinical Development.

Alterity Therapeutics Announces Publication Of Peer-Reviewed Study In NeuroImage Showing QSM MRI Can Detect Disease-Specific Iron Accumulation In Brains Of Patients With MSA

Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegenerative Disease With No Approved Disease-Modifying Treatments

Alerity Therapeutics Announces Presentation Of New Data Analyses From The Phase 2 Trial Of ATH434, Demonstrating Clinical Efficacy In Patients With Multiple System Atrophy At The American Academy of Neurology Annual Meeting

Alterity Therapeutics To Present ATH434 MSA Data At AAN Late‑Breaking Session, April 21; ATH434 Shows Disease‑Modifying Signal In MSA

Alterity Therapeutics To Present ATH434 MSA Data At AAN Late‑Breaking Session, April 21; ATH434 Shows Disease‑Modifying Signal In MSA

Alterity Therapeutics shares are trading higher after the company announced that it received regulatory feedback following a Type C Meeting with the FDA regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy.

Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Alterity Therapeutics Advances ATH434 In Late-Stage Clinical Development For Multiple System Atrophy

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics Reports A$49.2M Cash As Of Dec. 31, Strengthens ATH434 Phase 2 MSA Data And Advances FDA End-Of-Phase 2 Meeting Planning For Mid-2026

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

Alterity Targets $2.4B Market as Lead Drug Clears Phase 2 and Moves Toward Phase 3

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

Alterity Therapeutics Presents Data On Orthostatic Hypotension From Its ATH434-201 Phase 2 Clinical Study In Multiple System Atrophy

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report